Dengue vaccine could be ready by 2015: Sanofi

Jun 10, 2011

French drugs group Sanofi said Friday that its vaccine against dengue, a mosquito-borne infection that kills thousands of people around the world each year, could be launched in about four years.

"The vaccine could be available... around 2015," Jean Lang, head of at the group's subsidiary Sanofi-Pasteur, told reporters in Bangkok.

The launch date is dependent on regulatory approval in each country based on the results of trials.

The vaccine is the first for dengue to undergo advanced "Phase III" clinical trials -- the final stage before the results are submitted for regulatory approval.

About 4,000 children in the central Thai province of Ratchaburi, one of the worst affected areas in the country, are participating in a study that aims to establish the efficacy of the vaccine.

Dengue causes severe, in about 50 million people every year, mainly in developing countries. There are four strains, one of which is a potentially lethal type.

Dengue has reemerged in recent years as a serious public health threat in . There is currently no treatment, cure or vaccine.

Explore further: Booming mobile health app market needs more FDA oversight for consumer safety, confidence

add to favorites email to friend print save as pdf

Related Stories

Thailand developing dengue vaccine: researcher

Feb 22, 2011

Researchers in Thailand say they have developed a prototype vaccine against dengue fever and will conduct further tests with the aim of bringing it to market within a decade.

US researchers hopeful for dengue vaccine

Feb 17, 2011

Promising advances have been made in the testing of possible vaccines to prevent the mosquito-borne dengue virus, which kills 25,000 people every year, researchers said Thursday.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

User comments : 0